United Therapeutics Corporation (UTHR) financial statements and ratios from SEC XBRL: revenue $3.2B (TTM), net margin 41.9%, revenue growth -1.9% YoY, P/E 16.6. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $3.18B |
| Revenue (TTM) | $3.2B |
| Net Margin | 41.9% |
| Operating Margin (TTM) | 44.4% |
| Revenue Growth (YoY) | -1.9% |
| EPS Growth (YoY) | 14.0% |
| FCF Growth (YoY) | 58.8% |
| P/E Ratio | 16.6 |
| EV / EBITDA | 13.4 |
| Price / Book | 3.40 |
| Price / Sales | 6.90 |
| FCF Yield | 5.0% |
| Altman Z-Score | 20.24 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
UTHR overview · UTHR earnings · UTHR KPIs · UTHR documents · UTHR ownership · UTHR peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.